Published in
American Society of Hematology, Blood Advances, 24(1), p. 2193-2205, 2017
DOI: 10.1182/bloodadvances.2017010223
Links
Tools
Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells
Journal article published in 2017 by
Barbara Withers,
Emily Blyth 
,
Leighton E. Clancy,
Agnes Yong,
Chris Fraser,
Jane Burgess,
Renee Simms,
Rebecca Brown,
David Kliman ,
Ming-Celine Dubosq,
David Bishop ,
Gaurav Sutrave,
Chun Kei Kris Ma,
Peter J. Shaw,
Kenneth P. Micklethwaite
and other authors.
,
Leighton E. Clancy,
Agnes Yong,
Chris Fraser,
Jane Burgess,
Renee Simms,
Rebecca Brown,
David Kliman ,
Ming-Celine Dubosq,
David Bishop ,
Gaurav Sutrave,
Chun Kei Kris Ma,
Peter J. Shaw,
Kenneth P. Micklethwaite
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Postprint:
archiving forbidden
Data provided by 
Abstract
Key Points Partially HLA-matched third-party CMV-specific T cells provide long-term viral control in HSCT patients with resistant CMV infection. Viral control occurs in the setting of recovery of CD8+ terminally differentiated effector T cells.